{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:27:52Z","timestamp":1791239272024,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research and Development Program of Science and Technology Department of Yunnan Province","award":["202403AC100023"],"award-info":[{"award-number":["202403AC100023"]}]},{"name":"Kunming Medical University First-class Discipline Team (Superior Team) Construction Project","award":["2024XKTDYS04"],"award-info":[{"award-number":["2024XKTDYS04"]}]},{"name":"Second Affiliated Hospital of Kunming Medical University","award":["RCTDXK-202301"],"award-info":[{"award-number":["RCTDXK-202301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04665-0","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:34:58Z","timestamp":1770942898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary biliary cholangitis with inflammation involving zone 3 of the liver has a poor response to ursodeoxycholic acid treatment: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Huanqiao","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Kui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"4665_CR1","doi-asserted-by":"crossref","unstructured":"Kaplan MM, Gershwin ME. Primary Biliary Cirrhosis \u2014 NEJM[J]. 1996.","DOI":"10.1056\/NEJM199611213352107"},{"issue":"1","key":"4665_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","volume":"174","author":"ME Gershwin","year":"2010","unstructured":"Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells[. J] Immunological Reviews. 2010;174(1):210\u201325. https:\/\/doi.org\/10.1034\/j.1600-0528.2002.017402.x.","journal-title":"J] Immunological Reviews"},{"issue":"3","key":"4665_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12016-012-8324-0","volume":"43","author":"Kazuhito","year":"2012","unstructured":"Kazuhito. Kawata,Yoshimasa,et al.The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing Cholangitis[J]. Clin Rev Allergy Immunol. 2012;43(3):230\u201341. https:\/\/doi.org\/10.1007\/s12016-012-8324-0.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4665_CR4","unstructured":"Hirschfield GM, .Primary Biliary Cholangitis: Clinical Insights Into Diagnosis and Staging[J].Gastroenterology & hepatology. 2021, 17 5 Suppl 5:, 2\u20135."},{"key":"4665_CR5","doi-asserted-by":"publisher","unstructured":"Chung HL, Tan JR, Loo JH, et al. IDDF2025-ABS-0360 global epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis[J]. Gut. 2025;74(Sup3). https:\/\/doi.org\/10.1136\/gutjnl-2025-IDDF.173.","DOI":"10.1136\/gutjnl-2025-IDDF.173"},{"key":"4665_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12072-019-09984-x","volume":"13","author":"N Zeng","year":"2019","unstructured":"Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia\u2013Pacific region: a systematic review and meta-analysis[J]. Hep Intl. 2019;13:1333\u201341. https:\/\/doi.org\/10.1007\/s12072-019-09984-x.","journal-title":"Hep Intl"},{"key":"4665_CR7","doi-asserted-by":"publisher","unstructured":"Lindor KD, Bowlus CL, Boyer J et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2019.https:\/\/doi.org\/10.1002\/hep.30145","DOI":"10.1002\/hep.30145"},{"key":"4665_CR8","doi-asserted-by":"publisher","unstructured":"John BV, Khakoo NS, Schwartz KB, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated Cirrhosis[J]. Official J Am Coll Gastroenterol | ACG. 2021;116. https:\/\/doi.org\/10.14309\/ajg.0000000000001280.","DOI":"10.14309\/ajg.0000000000001280"},{"key":"4665_CR9","doi-asserted-by":"publisher","unstructured":"Ludwig J, Dickson ER, Mcdonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)[J].Virchows archiv A pathological anatomy and histology, 1978, 379(2):103\u201312.https:\/\/doi.org\/10.1007\/BF00432479","DOI":"10.1007\/BF00432479"},{"key":"4665_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ar.1091190103","volume":"119","author":"A Rappaport","year":"2010","unstructured":"Rappaport A, Borowy Z, Lougheed W. Subdivision of hexagonal liver lobules into a structural and functional unit. Role Hepatic Physiol pathology[J] Anat Record. 2010;119:11\u201333. https:\/\/doi.org\/10.1002\/ar.1091190103.","journal-title":"Role Hepatic Physiol pathology[J] Anat Record"},{"key":"4665_CR11","doi-asserted-by":"crossref","unstructured":"Corpechot C, Lemoinne S, Soret PA et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?[J].Hepatology, 2024, 79(1):1010.1097\/HEP.0000000000000529","DOI":"10.1097\/HEP.0000000000000529"},{"issue":"6","key":"4665_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ueg2.12095","volume":"9","author":"H Cortez-Pinto","year":"2021","unstructured":"Cortez-Pinto H, Liberal R, Lopes S, et al. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a National registry of liver disease. United Eur Gastroenterol J. 2021;9(6):699\u2013706. https:\/\/doi.org\/10.1002\/ueg2.12095.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"4665_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12072-021-10163-0","volume":"15","author":"N Kimura","year":"2021","unstructured":"Kimura N, Takamura M, Takeda N, et al. Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. Hepatol Int. 2021;15(2):437\u201343. https:\/\/doi.org\/10.1007\/s12072-021-10163-0.","journal-title":"Hepatol Int"},{"issue":"1","key":"4665_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"M Gideon","year":"2017","unstructured":"Gideon M. Hirschfield,et al.EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis -. ScienceDirect[J] J Hepatol. 2017;67(1):145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","journal-title":"ScienceDirect[J] J Hepatol"},{"key":"4665_CR15","doi-asserted-by":"crossref","unstructured":"Kawata KJ. SatoruShimoda, ShinjiYamashita, YukiYamashita, MahoKitsugi, KensukeTakatori, ShingoOhta, KazuyoshiIto, JunShimoyama, ShinNoritake, HidenaoSuda, TakafumiHarada, Kenichi.The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis[J]. Hepatol Research: Official J Japan Soc Hepatol, 2021, 51(1).","DOI":"10.1111\/hepr.13584"},{"issue":"1","key":"4665_CR16","doi-asserted-by":"publisher","first-page":"e3002955","DOI":"10.1371\/journal.pbio.3002955","volume":"23","author":"K Uno","year":"2025","unstructured":"Uno K, Uchino T, Suzuki T, et al. Rspo3-mediated metabolic liver zonation regulates systemic glucose metabolism and body mass in mice. PLoS Biol. 2025;23(1):e3002955. https:\/\/doi.org\/10.1371\/journal.pbio.3002955. Published 2025 Jan 24.","journal-title":"PLoS Biol"},{"key":"4665_CR17","doi-asserted-by":"publisher","first-page":"155830","DOI":"10.1016\/j.metabol.2024.155830","volume":"154","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhao Y, Carbonaro M, et al. Perturbed liver gene zonation in a mouse model of non-alcoholic steatohepatitis. Metabolism. 2024;154:155830. https:\/\/doi.org\/10.1016\/j.metabol.2024.155830.","journal-title":"Metabolism"},{"issue":"11","key":"4665_CR18","doi-asserted-by":"publisher","first-page":"e14239","DOI":"10.1111\/apha.14239","volume":"240","author":"SFJ van de Graaf","year":"2024","unstructured":"van de Graaf SFJ, Paulusma CC, In Het Panhuis W. Getting in the zone: metabolite transport across liver zones. Acta Physiol (Oxf). 2024;240(11):e14239. https:\/\/doi.org\/10.1111\/apha.14239.","journal-title":"Acta Physiol (Oxf)"},{"issue":"4","key":"4665_CR19","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.jhepr.2021.100315","volume":"3","author":"S Kurosaki","year":"2021","unstructured":"Kurosaki S, Nakagawa H, Hayata Y, et al. Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis. JHEP Rep. 2021;3(4):100315. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100315. Published 2021 May 27.","journal-title":"JHEP Rep"},{"key":"4665_CR20","doi-asserted-by":"publisher","unstructured":"Zhu H, Zheng M, He H et al. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study[J].BMC gastroenterology, 2023, 23(1).https:\/\/doi.org\/10.1186\/s12876-023-03031-8","DOI":"10.1186\/s12876-023-03031-8"},{"key":"4665_CR21","doi-asserted-by":"publisher","unstructured":"Ma W, Chen D. Immunological abnormalities in patients with primary biliary cholangitis.[J].Clinical science (London, England : 1979), 2019, 133(6):741\u201360.https:\/\/doi.org\/10.1042\/CS20181123","DOI":"10.1042\/CS20181123"},{"issue":"8","key":"4665_CR22","doi-asserted-by":"publisher","first-page":"12DOI","DOI":"10.1016\/j.cgh.2023.02.005","volume":"21","author":"C Levy","year":"2023","unstructured":"Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary Cholangitis[J]. Clin Gastroenterol Hepatol. 2023;21(8):12DOI. https:\/\/doi.org\/10.1016\/j.cgh.2023.02.005.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4665_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5152\/tjg.2023.22239","volume":"34","author":"R Barba Bernal","year":"2023","unstructured":"Barba Bernal R, Ferrigno B, Medina Morales E, et al. Management of primary biliary cholangitis: current treatment and future Perspectives[J]. Turk J Gastroenterol. 2023;34(2):89\u2013100. https:\/\/doi.org\/10.5152\/tjg.2023.22239.","journal-title":"Turk J Gastroenterol"},{"issue":"10","key":"4665_CR24","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.jhepr.2024.101168","volume":"6","author":"SB Roberts","year":"2024","unstructured":"Roberts SB, Choi WJ, Worobetz L, et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. JHEP Rep. 2024;6(10):101168. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101168.","journal-title":"JHEP Rep"},{"key":"4665_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/jrms.jrms_813_22","volume":"29","author":"SMJ Sajadi","year":"2024","unstructured":"Sajadi SMJ, Tamizifar B, Sanei MH, Babak A. Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010\u20132019[J]. J Res Med Sci. 2024;29:59. https:\/\/doi.org\/10.4103\/jrms.jrms_813_22.","journal-title":"J Res Med Sci"},{"key":"4665_CR26","doi-asserted-by":"publisher","unstructured":"Hofer BS, Burghart L, Halilbasic E et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J].Alimentary Pharmacology & therapeutics. 2024(8):59.https:\/\/doi.org\/10.1111\/apt.17908","DOI":"10.1111\/apt.17908"},{"issue":"4","key":"4665_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jcmgh.2024.01.005","volume":"17","author":"L Ceci","year":"2024","unstructured":"Ceci L, Gaudio E, Kennedy L. Cellular interactions and crosstalk facilitating biliary fibrosis in cholestasis. Cell Mol Gastroenterol Hepatol. 2024;17(4):553\u201365. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.01.005.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"4665_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/cells12050792","volume":"12","author":"SO Aseem","year":"2023","unstructured":"[Aseem SO, Hylemon PB, Zhou H. Bile acids and biliary fibrosis. Cells. 2023;12(5):792. https:\/\/doi.org\/10.3390\/cells12050792. Published 2023 Mar 2.","journal-title":"Cells"},{"issue":"1","key":"4665_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","volume":"17","author":"C Yang","year":"2023","unstructured":"Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int. 2023;17(1):237\u201348. https:\/\/doi.org\/10.1007\/s12072-022-10431-7.","journal-title":"Hepatol Int"},{"issue":"2","key":"4665_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jhep.2022.10.007","volume":"78","author":"F Nevens","year":"2023","unstructured":"Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases\u2020[J]. J Hepatol. 2023;78(2):430\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.007. Epub 2022 Oct 20. PMID: 36272496.","journal-title":"J Hepatol"},{"key":"4665_CR31","doi-asserted-by":"publisher","unstructured":"Aguilar MT, Chascsa DM. Update on emerging treatment options for primary biliary Cholangitis[J].Hepatic medicine: evidence and Research, 2020, 12:69\u201377.https:\/\/doi.org\/10.2147\/HMER.S205431","DOI":"10.2147\/HMER.S205431"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04665-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04665-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04665-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:33:31Z","timestamp":1774020811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04665-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4665"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04665-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Second Affiliated Hospital of Kunming Medical University. The requirement for informed consent was waived by Ethics Committee of the Second Affiliated Hospital of Kunming Medical University (KMMU2025MEC155) due to retrospective nature of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}